PharmaShots | Incisive News in 3 Shots

Subscribe Now

ionis pharmaceuticals

Ionis Reports the US FDA’s NDA Acceptance of Donidalorsen as a Prophylactic Treatment of Hereditary Angioedema (HAE)

Ionis Reports the US FDA’s NDA Acceptance of Donidalorsen as a Prophylactic Treatment of Hereditary Angioedema (HAE)

November 5, 2024

Ionis Reports Data from the P-III (OASIS-HAE) Trial of Donidalorsen for the Treatment of Hereditary Angioedema

Ionis Reports Data from the P-III (OASIS-HAE) Trial of Donidalorsen for the Treatment of Hereditary Angioedema

January 23, 2024

Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe

Ionis and Otsuka Sign License Agreement to Develop and Commercialize Donidalorsen for Hereditary Angioedema (HAE) in Europe

December 19, 2023

Ionis Pharmaceuticals Reports the Results for Donidalorsen in P-II Trial to Treat Type 1 and Type 2 Hereditary Angioedema

Ionis Pharmaceuticals Reports the Results for Donidalorsen in P-II Trial to Treat Type 1 and Type 2 Hereditary Angioedema

November 10, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us